Clinical Trials Directory

Trials / Completed

CompletedNCT02439736

EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY

A PROSPECTIVE CLINICAL EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY

Status
Completed
Phase
Study type
Observational
Enrollment
119 (actual)
Sponsor
Banyan Biomarkers, Inc · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to evaluate Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of CT-positive subjects (as determined by an independent Neuroimaging Review Committee) presenting acutely with traumatic brain injury (Glasgow Coma Scale score 9-15).

Conditions

Interventions

TypeNameDescription
OTHERBlood draw within 12 hours of head injury

Timeline

Start date
2015-06-01
Primary completion
2016-11-01
Completion
2016-11-01
First posted
2015-05-12
Last updated
2017-08-08

Locations

7 sites across 2 countries: United States, Germany

Source: ClinicalTrials.gov record NCT02439736. Inclusion in this directory is not an endorsement.

EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY (NCT02439736) · Clinical Trials Directory